8-K current report · filed Oct 9, 2026

Atrium Therapeutics, Inc. (RNA) 8-K Current Report: October 9, 2026

Item 8.01RNA overview

Short answer

Atrium Therapeutics, Inc. (RNA) filed an 8-K current report with the SEC on October 9, 2026 reporting Item 8.01 (Other Events). Proposed PIPE issuance: 5,170,384 common shares plus pre-funded warrants for 1,134,930 shares.

Atrium Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Proposed PIPE issuance: 5,170,384 common shares plus pre-funded warrants for 1,134,930 shares
  • Post-offering share count expected at 21,571,507, indicating material potential dilution
  • Offering remains subject to closing conditions, creating execution and timing risk
  • Shares include settlement of make-whole equity awards from the Avidity Biosciences spin-off

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Atrium Therapeutics, Inc. 8-K filings

Get the next RNA 8-K as it lands

Follow RNA for push alerts, or ask the research agent what this filing means.